PT  - JOURNAL ARTICLE
AU  - Calais, Jeremie
AU  - Fendler, Wolfgang P.
AU  - Herrmann, Ken
AU  - Eiber, Matthias
AU  - Ceci, Francesco
TI  - Comparison of <sup>68</sup>Ga-PSMA-11 and <sup>18</sup>F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence
AID  - 10.2967/jnumed.117.203257
DP  - 2018 May 01
TA  - Journal of Nuclear Medicine
PG  - 789--794
VI  - 59
IP  - 5
4099  - http://jnm.snmjournals.org/content/59/5/789.short
4100  - http://jnm.snmjournals.org/content/59/5/789.full
SO  - J Nucl Med2018 May 01; 59
AB  - This was a head-to-head comparison between 68Ga-labeled prostate-specific membrane antigen (PSMA)-11 and 18F-fluciclovine PET/CT in a series of 10 patients with prostate cancer (PCa) recurrence. Methods: In total, 288 patients with PCa recurrence were enrolled in a prospective study of 68Ga-PSMA-11 PET/CT imaging for recurrent disease localization (ClinicalTrials.gov identifier NCT02940262). We retrospectively identified 10 patients who underwent clinically indicated 18F-fluciclovine PET/CT prior to enrollment. Results: The median time between the 2 scans was 2.2 mo (range, 0.2–4.2 mo). The median prostate-specific antigen (PSA) value was 1.0 ng/mL (mean, 4.7 ng/mL; range, 0.13–18.1 ng/mL) and 1.1 ng/mL (mean, 6.2 ng/mL; range, 0.24–31.3 ng/mL) at the time of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT, respectively. Five of 10 patients (50%) were negative with 18F-fluciclovine but positive with 68Ga-PSMA-11 PET/CT. Two of 10 patients (20%) were positive with both 18F-fluciclovine and 68Ga-PSMA-11 PET/CT, but 68Ga-PSMA-11 PET/CT showed additional lymph nodes metastasis. Three of 10 patients (30%) were negative with both 18F-fluciclovine and 68Ga-PSMA-11 PET/CT. Conclusion: This case series suggests improved detection rates for 68Ga-PSMA-11 PET/CT when compared with 18F-fluciclovine PET/CT in patients with recurrent PCa. Prospective trials designed to directly compare the two should be initiated.